

Topical anticholinergic medications for primary hyperhidrosis: A protocol for a systematic review and meta-analysis

Yang Wu¹⁺, Wenli Gao²⁺, Jiao Yan¹, Min Yang^{1*}, Dongyang Gao^{3*}

¹ Department of Integrated Chinese and Western Medicine, The General Hospital of Western Theater Command, Chengdu, Sichuan, P.R. China.

² Tianjin University of Traditional Chinese Medicine, Tianjin, China.

³ School of Life Sciences, Beijing University of Chinese Medicine, Beijing, China.

* Correspondence: translie@live.cn (M.Y.); 20200941085@bucm.edu.cn (D.G.)

+ These authors have contributed equally to this work and share first authorship.

Abstract

Background: Primary hyperhidrosis (PHH) is a chronic condition characterized by excessive sweating. Several topical anticholinergic agents have been developed, but the evidence for the efficacy and tolerability of changing medication pathways of anticholinergics for PHH is limited. We will review the available literature to derive information regarding the efficacy and safety of different medicines used for the topical treatment of patients with hyperhidrosis. **Methods:** PubMed, Cochrane Library, Embase, Web of Science, and Cochrane Central Register of Controlled Trials will be searched from inception to May 2023 for studies that may be eligible for inclusion. Randomized controlled trials (RCTs) of PHH treated with topical anticholinergic drugs will be included in the analysis. The primary outcomes will include the severity of hyperhidrosis measured quantitatively, the Hyperhidrosis Disease Severity Scale (HDSS) score, or the proportion of subjects with a minimum 2-grade improvement from baseline in HDSS, the Hyperhidrosis Disease Severity

26 Measure-Axillary (HDSM-Ax) score, and Dermatology Life Quality Index (DLQI).
 27 The secondary outcomes will focus on safety and tolerability. Study selection, data
 28 extraction, and assessment of the risk of bias will be independently performed by two
 29 investigators. Data synthesis will be performed using Review Manager 5.4 software.
 30 **Results:** The results will be published as a peer-reviewed article. **Conclusions:** This
 31 review will systematically evaluate the existing evidence on the efficacy and safety of
 32 topical anticholinergic agents in the treatment of PHH. These conclusions will provide
 33 supporting evidence for the current guidelines and more reliable evidence-based
 34 medicine references for clinical practitioners and researchers.

35 **PROSPERO registration number:** CRD42022312316

36 **Keywords:** Primary hyperhidrosis; anticholinergic drugs; topical; systematic review
 37

38 **Introduction**

39 Hyperhidrosis (HH) is a chronic disease in which the degree of sweating exceeds the
 40 physiological requirements for maintaining internal temperature regulation [1, 2]. HH
 41 is characterized by excessive local or systemic sweating due to exocrine sweat gland
 42 hyperfunction [3, 4], commonly found in areas such as axillae, palms, soles, and face
 43 [5, 6]. Hyperhidrosis is divided into primary hyperhidrosis (PHH) and secondary
 44 hyperhidrosis, based on whether there is an underlying disease or drug use [2, 7]. The
 45 prevalence of HH ranges from 1% to 4.8% [8, 9], and is seen in both in children and
 46 adults. The average age of onset is 14-25 years [10]. The discomfort associated with
 47 severe hyperhidrosis can interfere with daily life and even lead to social and work

48 isolation [11-13], with significant negative effects on the patient's daily activities,
49 mental health, and professional behavior [14, 15].

50 The pathophysiology, diagnosis, and treatment of PHH have attracted considerable
51 attention. Perspiration is produced by the secretion of sweat glands innervated by the
52 cholinergic nerve fibers of the sympathetic nervous system [16]. Studies suggest that
53 hyperactivity of cholinergic nerve fibers in sweat glands may lead to PHH [17]. In
54 addition, an excessive number or abnormal distribution of sweat glands may also be
55 the cause of the disease [18]. The anterior cingulate cortex, which controls responses
56 to emotional stimuli, also exerts a significant influence [19].

57 Management of PHH includes systemic, local, psychological, and surgical treatments.
58 [16] Systemic therapies include oral anticholinergic drugs [20] such as oxybutynin
59 [21]. Topical treatment includes the use of alumina, which chemically blocks sweat
60 ducts to reduce sweating [22], as well as topical anticholinergic agents, such as
61 glycopyrronium bromide. Ion import at specific sites is usually the treatment of
62 choice for HH of the palms and soles, but long-term maintenance treatment is
63 required [23]. Botulinum toxin type A (Botox, approved by the Food and Drug
64 Administration (FDA) in 2004 [6] and subsequently by several countries [24] is the
65 first- or second-line treatment option for axillary and plantar hyperhidrosis [25]. This
66 toxin blocks cholinergic stimulation of sweat glands. Psychotherapy is beneficial in
67 some cases [26, 27]. Surgery, including local surgery and endoscopic thoracic
68 sympathetic nerve resection, can be considered when conservative treatment fails [7,
69 28].

70 However, these treatments are associated with side effects and complications.

71 Adverse events associated with oral anticholinergics, such as dry mouth, urinary

72 retention, constipation, and headache [29], often lead to interruption of drug use and

73 even increase the risk of cognitive impairment [30]. Studies have shown that its

74 efficacy decreases with long-term treatment [31]. Other adverse effects include skin

75 irritation, pain, and burns caused by ion import [32], repeated injections of Botox [16],

76 and compensatory sweating after sympathetic nerve resection [33, 34].

77 Therefore, improving the tolerability of preparations has become the focus of research,

78 especially in the development of preparations for external use [35]. Several topical

79 anticholinergic drugs have been approved in recent years. Glycopyrronium tosylate

80 (Qbrexza™, a pre-wetting cloth containing 2.4% glycopyrronium solution) reduces

81 sweating by blocking the activation of acetylcholine receptors in the peripheral sweat

82 glands [15] and was approved by the FDA in 2018 [36]. Topical sofpironium

83 bromide (ECCLOCK®, 5%) gel reduces sweat secretion by inhibiting local sweat

84 gland M3 muscarinic receptor [37], it was approved in Japan in September 2020. In

85 addition, topical oxybutynin chloride cream or gel formulations have shown good

86 tolerability, and promise to be of benefit in the future [38]. Topical preparation of

87 glycopyrronium bromide has aroused interest as a treatment option for PHH [39], and

88 1% glycopyrronium bromide cream has completed the phase IIIa study [40]. The

89 dermal preparation of umeclidinium ammonium bromide is also under way [41].

90 Previous meta-analyses have assessed the efficacy and safety of oral anticholinergic

91 agents (oxybutynin, methane bromide, glycopyrrolate, etc.) for the treatment of PHH

92 and have shown that improved outcomes are associated with a large number of
93 adverse events [5]. There are currently several topical anticholinergic agents on the
94 market, and the evidence for the efficacy and tolerability of a change in the route of
95 administration in the treatment of PHH has not been thoroughly evaluated. Therefore,
96 systematic reviews and meta-analyses are necessary to provide supporting evidence
97 for the current guidelines and more reliable evidence-based medicine references for
98 clinical practitioners and researchers.

99 **Materials and Methods**

100 **Study registration**

101 This meta-analysis protocol follows the Preferred Reporting Items for Systematic
102 Review and Meta-Analysis Protocols (PRISMA-P) [42] and the Manual for
103 Systematic Evaluation of Cochrane Interventions. The PRISMA-P checklist is in S1
104 Appendix. The protocol has been registered with the International Prospective
105 Register of Systematic Reviews (PROSPERO) (CRD42022312316). The
106 investigators will receive consistent training to ensure that they are familiar with the
107 background, purpose, and methodology of the system evaluation.

108 **Eligibility criteria**

109 **Type of studies**

110 Randomized controlled trials (RCTs) of PHH treated with topical anticholinergic
111 drugs will be included. Completed trials published on a clinical trial registration
112 platform will also be included. Quasi-randomized trials will be excluded.

113 **Types of participants**

114 Participants with a diagnosis of primary hyperhidrosis based on focal, visible,
115 excessive sweating for at least 6 months without apparent cause, and meeting two or
116 more of the following criteria at the same time: (1) onset age of 25 years or younger,
117 (2) bilateral and relatively symmetric distribution, (3) at least one episode weekly, (4)
118 cessation of sweating during sleep, (5) impaired daily activities, and (6) family history
119 of primary hyperhidrosis will be included. Participants will have to have a
120 hyperhidrosis disease severity scale (HDSS) score of at least three during the baseline
121 evaluation.

122 Patients with secondary hyperhidrosis will be excluded from this study. Patients will
123 be excluded if they have another concurrent cutaneous or subcutaneous disease or if
124 they have received any treatment or undergone any procedure that could interfere with
125 drug activity.

126 **Type of interventions and controls**

127 RCTs comparing topical anticholinergics such as glycopyrronium tosylate,
128 sofpironium bromide, umeclidinium, or oxybutinin with placebo, and RCTs
129 comparing two types of aforementioned topical anticholinergics will be included.
130 Trials comparing the same type of anticholinergic drugs at different concentrations or
131 treatment durations will be considered as eligible. Trials involving combination
132 therapy (e.g., a combination of topical and oral anticholinergic drugs) will be
133 excluded.

134 **Type of outcome measures**

135 Primary outcomes: (1) Severity of hyperhidrosis measured quantitatively (e.g.,
136 gravimetry, evaporimeter, and minor starch-iodine test). (2) Hyperhidrosis Disease
137 Severity Scale (HDSS) score or the proportion of subjects with a minimum 2-grade
138 improvement from baseline in the HDSS. (3) Hyperhidrosis Disease Severity
139 Measure-Axillary (HDSM-Ax) score. (4) Dermatology Life Quality Index (DLQI).
140 Secondary outcomes: Safety and tolerability will be evaluated using the following
141 outcomes: (1) total number of patients who experienced treatment-emergent adverse
142 events (TEAEs) such as blurred vision or mydriasis, dry mouth, urinary retention,
143 constipation, anhidrosis, dizziness, headache, nasopharyngitis, etc.; (2) total number
144 of patients who experienced local skin reactions (LSRs), including burning, stinging,
145 pruritus, edema, erythema, dryness, and scaling; and (3) total number of patients who
146 experienced serious adverse events (according to the classification employed by the
147 US FDA).

148 **Data sources and search strategies**

149 PubMed, Cochrane Library, Embase, Web of Science, and Cochrane Central Register
150 of Controlled Trials will be searched from inception to May 2023 for studies that may
151 be eligible for inclusion. In addition, we will identify other studies that meet the
152 inclusion criteria from the list of references included in the study. Clinical trial
153 registries, such as clinicaltrials.gov and WHO ICTRP, will also be searched for
154 ongoing or unpublished clinical trials.

155 Two investigators (YW and WG) independently searched the literature using a
156 combination of medical subject heading (MeSH) terms and free-text terms, and

157 designed a search formula for each electronic database, including "hyperhidrosis,"
158 "anticholinergic drugs," and "randomized controlled trials". There were no language
159 restrictions in the search process. PubMed's search strategy is shown in S2 Appendix
160 and will be modified to meet the needs of other databases.

161 **Studies selection**

162 The literature will be screened independently by two investigators (YW and WG)
163 according to pre-established inclusion and exclusion criteria. The search results will
164 be imported into Endnote X9.0, and duplicated data will be deleted. The titles and
165 abstracts of the studies were read independently to screen out irrelevant studies and
166 records. The full paper will then be read and non-randomized controlled trials,
167 unqualified controls, and duplicate studies will be excluded. Any discrepancies in the
168 screening process will be resolved through discussion with a third investigator (DG).
169 The details of study selection are summarized in a flow chart (Figure 1).

170 **Data extraction and management**

171 Two investigators (WG and JY) independently extracted the data using standard
172 Excel spreadsheets, including the first author, year of publication, country, research
173 type, research design, baseline information for each group, intervention, treatment
174 time, outcome indicators, and adverse reactions. The extracted data will be
175 crosschecked. If there is any discrepancy, the original article will be checked and the
176 discrepancy resolved by consensus. When data are not reported in a usable format and
177 are difficult to reliably extract, the authors will be contacted by email for information
178 twice over four weeks. If some data are still not available from authors, they can be

179 acquired based on available data referring to advanced methods of data extraction,
180 such as intercepting data from a statistical graph and data conversion. [43]

181 **Assessment of risk of bias**

182 The Cochrane Risk Assessment of Bias Tool [44] will be applied by two investigators
183 (YW and WG) to independently assess the risk of bias in the included RCTs. The
184 assessment includes random sequence generation, allocation concealment, blinding of
185 participants and personnel, blinding of outcome assessment, incomplete outcome data,
186 selective reporting, and other biases. The criteria used to assess the risk of bias are
187 "low risk," "high risk" and "unclear [44]". Disagreements regarding the risk of bias
188 will be resolved by consultation with a third investigator (DG). A bias risk assessment
189 chart will be generated to present the assessment results and details.

190 **Statistical analysis**

191 Review Manager 5.4 software [42] (Copenhagen: The Nordic Cochrane Centre, The
192 Cochrane Collaboration) will be used for data synthesis and statistical analysis. For
193 dichotomous variables, relative risk (RR), risk difference (RD), 95% confidence
194 interval (CI), and P-values will be calculated. For continuous variables, the mean
195 difference (MD) or standard mean difference (SMD), 95% confidence interval (CI),
196 and P-values will be calculated using the random-effects model. Simultaneously, the
197 Q test and I² index will be used to assess statistical heterogeneity. When
198 heterogeneity is significant (I²>50%), we will first explore the possible sources of
199 heterogeneity. A sensitivity analysis will be performed to examine the sources of
200 heterogeneity. When there is clinical or methodological heterogeneity, subgroup

201 analysis or meta-regression(with Stata V.16.0 software) will be performed. [42] When
202 there is statistical heterogeneity, a random-effects model will be used. Finally, if
203 considerable heterogeneity cannot be resolved, a systematic review of descriptive
204 analyses will be performed instead of a meta-analysis.

205 **Dealing with missing data**

206 If there is missing data from the included RCT studies, the original articles,
207 supplemental materials, and even other articles published based on the same trial will
208 be scrutinized again for omissions. Otherwise, the investigators will attempt to contact
209 the corresponding author of the study by email twice over 4 weeks. If complete data
210 are not available, the study will not be included. The potential impact of missing data
211 will be assessed using a sensitivity analysis, as described in the results.

212 **Subgroup analysis and sensitivity analysis**

213 Subgroup analysis based on different comparisons and different skin sites (forehead,
214 axillae, palms, etc.) where the drugs are applied will be conducted. If there is
215 significant heterogeneity, the trials will be further classified to perform a subgroup
216 analysis after exploration. A sensitivity analysis will be performed to evaluate the
217 robustness of the results and to explore the source of heterogeneity. In addition, given
218 the different results between the same risk of bias domain of studies, studies can be
219 divided into different subgroups based on "low risk", "high risk of bias", and "not
220 clear" to compare the difference in the estimate of effect and analyze the contribution
221 of subgroups to the pooled effect size, which is conducive to grade the quality of
222 evidence.

223 **Publication bias**

224 When more than 10 studies met the inclusion criteria, we will evaluate the potential
225 publication bias by drawing funnel plots (with Review Manager 5.4 software) and
226 Egger tests (with Stata V.16.0 software).

227 **Grading the quality of evidence**

228 We will evaluate the evidence quality of the included studies according to the Grading
229 of Recommendations Assessment, Development, and Evaluation (GRADE) approach
230 [45] The evidence quality GRADE is divided into four grades: high, moderate, low,
231 and very low.

232 **Results**

233 The results of this systematic review will be published as a peer-reviewed article.

234 **Discussion**

235 Although there are many therapeutic options for PHH, treatment plans should be
236 individualized according to the actual situation of patients[35]. Clinical guidelines for
237 PHH no longer recommend systemic therapy because of unacceptable adverse
238 reactions to oral anticholinergic drugs in recent years[46]. Topical anticholinergic
239 agents optimize existing therapies and are likely to replace systemic oral
240 administration[17].

241 This review will systematically evaluate the existing evidence on the efficacy and
242 safety of topical anticholinergic agents in the treatment of PHH. These conclusions
243 will help clinicians or practitioners to develop individual and more optimal treatment

options for patients with PHH and provide supporting evidence for health policymakers and the current guidelines.

Conclusions

This systematic review aims to provide comprehensive evidence on the efficacy and safety of topical anticholinergic agents for primary hyperhidrosis. The findings of this review may help point to better forms of treatment based on evidence-based medicine.

Author Contributions:

Conceptualization, D.G. and Y.W.; methodology, W.G.; software, D.G.; validation, W.G., M.Y. and Y.W.; formal analysis, D.G.; investigation, Y.W.; resources, Y.W.; data curation, W.G. and J.Y.; writing—original draft preparation, Y.W. and W.G.; writing—review and editing, D.G.; visualization, D.G.; supervision, M.Y.; project administration, M.Y.; funding acquisition, M.Y. All authors have read and agreed to the published version of the manuscript.”

Funding:

This work was supported by the Hospital Management Project of the General Hospital of Western Theater Command, Grant Number: 2021-XZYG-B34. The sponsor and funder had and will not have a role in the study design, data collection, and analysis.

Competing interests: None declared.

Author information:

Yang Wu (first author): Ph.D. Email: betteryy@126.com.

Wenli Gao(first author): Dr. Email: 18406564543@163.com

266 **Dongyang Gao (Correspondence author):** Ph.D. Email:

267 20200941085@bucm.edu.cn

268 **Min Yang(Correspondence author):** Ph.D. Email: translie@live.cn

269 **Jiao Yan:** Dr. Email: 312859465@qq.com

270

271 **References :**

272 1. Caserta F, Lenn J, Hofland H. Variables Affecting Delivery of Glycopyrronium Tosylate

273 Through Human Skin In Vitro. J Drugs Dermatol. 2020;19(11):1080-5. Epub 2020/11/17. doi:

274 10.36849/jdd.2020.5062. PubMed PMID: 33196749.

275 2. Liu V, Farshchian M, Potts GA. Management of Primary Focal Hyperhidrosis: An

276 Algorithmic Approach. J Drugs Dermatol. 2021;20(5):523-8. Epub 2021/05/04. doi:

277 10.36849/jdd.5774. PubMed PMID: 33938689.

278 3. Wolosker N, Kauffman P, de Campos JRM, Faustino CB, da Silva MFA, Teivelis MP, et al.

279 Long-term results of the treatment of primary hyperhidrosis with oxybutynin: follow-up of 1,658

280 cases. Int J Dermatol. 2020;59(6):709-15. Epub 2020/04/18. doi: 10.1111/ijd.14872. PubMed

281 PMID: 32301117.

282 4. Basedow S, Kruse R, Bruch-Gerharz D. [Hyperhidrosis of childhood and adolescence:

283 clinical aspects and therapeutic options]. Hautarzt. 2011;62(12):928-34. Epub 2011/10/12. doi:

284 10.1007/s00105-011-2225-7. PubMed PMID: 21987173.

285 5. Cruddas L, Baker DM. Treatment of primary hyperhidrosis with oral anticholinergic

286 medications: a systematic review. J Eur Acad Dermatol Venereol. 2017;31(6):952-63. Epub

287 2016/12/16. doi: 10.1111/jdv.14081. PubMed PMID: 27976476.

288 6. Cohen JL, Cohen G, Solish N, Murray CA. Diagnosis, impact, and management of focal
289 hyperhidrosis: treatment review including botulinum toxin therapy. *Facial Plast Surg Clin North*
290 *Am.* 2007;15(1):17-30, v-vi. Epub 2007/02/24. doi: 10.1016/j.fsc.2006.10.002. PubMed PMID:
291 17317552.

292 7. McConaghy JR, Fosselman D. Hyperhidrosis: Management Options. *Am Fam Physician.*
293 2018;97(11):729-34. Epub 2018/09/15. PubMed PMID: 30215934.

294 8. Delort S, Marchi E, Corrêa MA. Oxybutynin as an alternative treatment for hyperhidrosis.
295 *An Bras Dermatol.* 2017;92(2):217-20. Epub 2017/05/26. doi:
296 10.1590/abd1806-4841.201755126. PubMed PMID: 28538882; PubMed Central PMCID:
297 PMC5429108.

298 9. Ram R, Lowe NJ, Yamauchi PS. Current and emerging therapeutic modalities for
299 hyperhidrosis, part 1: conservative and noninvasive treatments. *Cutis.* 2007;79(3):211-7. Epub
300 2007/08/07. PubMed PMID: 17674587.

301 10. Kumar MG, Foreman RS, Berk DR, Bayliss SJ. Oral glycopyrrolate for refractory pediatric
302 and adolescent hyperhidrosis. *Pediatr Dermatol.* 2014;31(1):e28-30. Epub 2013/11/26. doi:
303 10.1111/pde.12236. PubMed PMID: 24266878.

304 11. Callejas MA, Grimalt R, Cladellas E. [Hyperhidrosis update]. *Actas Dermosifiliogr.*
305 2010;101(2):110-8. Epub 2010/03/13. doi: 10.1016/j.ad.2009.09.004. PubMed PMID:
306 20223153.

307 12. Bajaj V, Langtry JA. Use of oral glycopyrronium bromide in hyperhidrosis. *Br J Dermatol.*
308 2007;157(1):118-21. Epub 2007/04/27. doi: 10.1111/j.1365-2133.2007.07884.x. PubMed
309 PMID: 17459043.

- 310 13. Nyamekye IK. Current therapeutic options for treating primary hyperhidrosis. Eur J Vasc
311 Endovasc Surg. 2004;27(6):571-6. Epub 2004/05/04. doi: 10.1016/j.ejvs.2004.01.023.
312 PubMed PMID: 15121105.
- 313 14. Rzany B, Müller C, Hund M. [Focal hyperhidrosis.Quality of life, socioeconomic
314 importance and use of internal medicinal therapy]. Hautarzt. 2012;63(6):456-61. Epub
315 2012/06/20. doi: 10.1007/s00105-012-2331-1. PubMed PMID: 22710840.
- 316 15. Nwannunu CE, Limmer AL, Coleman K, Shah R, Patel RR, Mui UN, et al. Glycopyrronium
317 Tosylate (Qbrexza) for Hyperhidrosis. Skin Therapy Lett. 2019;24(2):1-3. Epub 2019/04/11.
318 PubMed PMID: 30970203.
- 319 16. Connolly M, de Berker D. Management of primary hyperhidrosis: a summary of the
320 different treatment modalities. Am J Clin Dermatol. 2003;4(10):681-97. Epub 2003/09/26. doi:
321 10.2165/00128071-200304100-00003. PubMed PMID: 14507230.
- 322 17. Wechter T, Feldman SR, Taylor SL. The Treatment of Primary Focal Hyperhidrosis. Skin
323 Therapy Lett. 2019;24(1):1-7. Epub 2019/03/01. PubMed PMID: 30817880.
- 324 18. Sammons JE, Khachemoune A. Axillary hyperhidrosis: a focused review. J Dermatolog
325 Treat. 2017;28(7):582-90. Epub 2017/03/21. doi: 10.1080/09546634.2017.1309347. PubMed
326 PMID: 28318360.
- 327 19. Eisenach JH, Atkinson JL, Fealey RD. Hyperhidrosis: evolving therapies for a
328 well-established phenomenon. Mayo Clin Proc. 2005;80(5):657-66. Epub 2005/05/13. doi:
329 10.4065/80.5.657. PubMed PMID: 15887434.
- 330 20. Baumgartner FJ, Bertin S, Konecny J. Superiority of thoracoscopic sympathectomy over
331 medical management for the palmo-plantar subset of severe hyperhidrosis. Ann Vasc Surg.

332 2009;23(1):1-7. Epub 2008/07/16. doi: 10.1016/j.avsg.2008.04.014. PubMed PMID:
333 18619780.

334 21. Nicholas R, Quddus A, Baker DM. Treatment of Primary Craniofacial Hyperhidrosis: A
335 Systematic Review. Am J Clin Dermatol. 2015;16(5):361-70. Epub 2015/06/10. doi:
336 10.1007/s40257-015-0136-6. PubMed PMID: 26055729.

337 22. Pariser DM, Ballard A. Topical therapies in hyperhidrosis care. Dermatol Clin.
338 2014;32(4):485-90. Epub 2014/08/26. doi: 10.1016/j.det.2014.06.008. PubMed PMID:
339 25152341.

340 23. Kim WO, Kil HK, Yoon DM, Cho MJ. Treatment of compensatory gustatory hyperhidrosis
341 with topical glycopyrrolate. Yonsei Med J. 2003;44(4):579-82. Epub 2003/09/02. doi:
342 10.3349/ymj.2003.44.4.579. PubMed PMID: 12950111.

343 24. Murray CA, Cohen JL, Solish N. Treatment of focal hyperhidrosis. J Cutan Med Surg.
344 2007;11(2):67-77. Epub 2007/03/22. doi: 10.2310/7750.2007.00012. PubMed PMID:
345 17374317.

346 25. Reisfeld R, Berliner KI. Evidence-based review of the nonsurgical management of
347 hyperhidrosis. Thorac Surg Clin. 2008;18(2):157-66. Epub 2008/06/19. doi:
348 10.1016/j.thorsurg.2008.01.004. PubMed PMID: 18557589.

349 26. Glaser DA, Hebert AA, Pariser DM, Solish N. Primary focal hyperhidrosis: scope of the
350 problem. Cutis. 2007;79(5 Suppl):5-17. Epub 2007/06/29. PubMed PMID: 17596096.

351 27. Maillard H, Lecouflet M. [Management of hyperhidrosis]. Ann Dermatol Venerol.
352 2015;142(4):252-61. Epub 2015/02/24. doi: 10.1016/j.annder.2014.11.005. PubMed PMID:
353 25697587.

354 28. Nawrocki S, Cha J. The etiology, diagnosis, and management of hyperhidrosis: A
355 comprehensive review: Therapeutic options. *J Am Acad Dermatol*. 2019;81(3):669-80. Epub
356 2019/02/03. doi: 10.1016/j.jaad.2018.11.066. PubMed PMID: 30710603.

357 29. Campanati A, Gregoriou S, Consales V, Rizzetto G, Bobyr I, Diotallevi F, et al. Combined
358 treatment of palmar hyperhidrosis with botulinum toxin type A and oxybutynin chloride: Results
359 of a clinical, multicenter, prospective study. *Dermatologic Therapy*. 2020;33(6):e14039. doi:
360 10.1111/dth.14039. PubMed PMID: 32691938.

361 30. Gregoriou S, Kontochristopoulos G, Tiligada E. Pharmacokinetic profile data of
362 glycopyrronium bromide 1% cream beyond 2 weeks are important. *The British Journal of*
363 *Dermatology*. 2021;185(2):467-8. doi: 10.1111/bjd.20088. PubMed PMID: 33792896.

364 31. Del Boz Gonzalez J, Rodríguez Barón D, Millán-Cayetano JF, de Troya Martin M.
365 Tolerance of oral oxybutynin in the treatment of hyperhidrosis. *Dermatol Ther*.
366 2020;33(6):e14197. Epub 2020/08/15. doi: 10.1111/dth.14197. PubMed PMID: 32794595.

367 32. Shimizu H, Tamada Y, Shimizu J, Ohshima Y, Matsumoto Y, Sugeno Y. Effectiveness
368 of iontophoresis with alternating current (AC) in the treatment of patients with palmoplantar
369 hyperhidrosis. *J Dermatol*. 2003;30(6):444-9. Epub 2003/06/18. doi:
370 10.1111/j.1346-8138.2003.tb00414.x. PubMed PMID: 12810991.

371 33. Cladellas E, Callejas MA, Grimalt R. A medical alternative to the treatment of
372 compensatory sweating. *Dermatol Ther*. 2008;21(5):406-8. Epub 2008/10/11. doi:
373 10.1111/j.1529-8019.2008.00222.x. PubMed PMID: 18844718.

374 34. Costa Ada S, Jr., Leão LE, Succi JE, Perfeito JA, Filho Castelo A, Rymkiewicz E, et al.
375 Randomized trial - oxybutynin for treatment of persistent plantar hyperhidrosis in women after

376 sympathectomy. Clinics (Sao Paulo). 2014;69(2):101-5. Epub 2014/02/13. doi:
377 10.6061/clinics/2014(02)05. PubMed PMID: 24519200; PubMed Central PMCID:
378 PMCPMC3912338.

379 35. Brown AL, Gordon J, Hill S. Hyperhidrosis: review of recent advances and new
380 therapeutic options for primary hyperhidrosis. Curr Opin Pediatr. 2014;26(4):460-5. Epub
381 2014/06/07. doi: 10.1097/mop.000000000000108. PubMed PMID: 24905102.

382 36. Glaser DA, Hebert AA, Nast A, Werschler WP, Green L, Mamelok RD, et al. A 44-Week
383 Open-Label Study Evaluating Safety and Efficacy of Topical Glycopyrronium Tosylate in
384 Patients with Primary Axillary Hyperhidrosis. Am J Clin Dermatol. 2019;20(4):593-604. Epub
385 2019/05/22. doi: 10.1007/s40257-019-00446-6. PubMed PMID: 31111409; PubMed Central
386 PMCID: PMCPMC6687675 Biotech, Inc., Dermira, Inc., Evolus, and Sienna
387 Biopharmaceuticals, Inc. and a consultant for Dermira, Inc. William P. Werschler is a
388 consultant and investigator for Dermira, Inc. Adelaide A. Herbert is a consultant for Dermira,
389 Inc. and an employee of the UTHealth McGovern Medical School, which received
390 compensation from Dermira, Inc. for study participation. Alexander Nast is an employee of
391 Charité – Universitätsmedizin Berlin, which received compensation from Dermira, Inc. for
392 study participation; he was an advisory board member for Boehringer Ingelheim, carried out
393 educational activities for Bayer and Novartis, and received research grants from Eli Lilly and
394 Company, Pfizer, GSK, Plc., and MEDA. Lawrence Green is an investigator for Brickell
395 Biotech, Inc. and an advisory board member and investigator for Dermira, Inc. Richard D.
396 Mamelok is a consultant for Dermira, Inc. John Quiring is an employee of QST Consultations.
397 Janice Drew is an employee of Dermira, Inc. David M. Pariser is a consultant and investigator

398 for Brickell Biotech, Inc., Celgene Corporation, Dermira, Inc., LEO Pharma US, Novartis
399 Pharmaceuticals, Promius Pharmaceuticals, Regeneron, and Valeant Pharmaceuticals
400 International, a consultant for ATACAMA, Biofrontera AG, DUSA Pharmaceuticals, Inc., Sonofi,
401 TDM SurgiTech, Inc., and TheraVida, and an investigator for Abbott Laboratories, Amgen,
402 Asana Biosciences, Dermavant Sciences, Eli Lilly and Company, Merck & Co., Inc., Novo
403 Nordisk A/S, Ortho Dermatologics, Peplin Inc., Pfizer Inc., Photocure ASA, and Stiefel (as
404 GSK company).

405 37. Paik J. Sofpironium Bromide: First Approval. *Drugs*. 2020;80(18):1981-6. Epub
406 2020/11/26. doi: 10.1007/s40265-020-01438-1. PubMed PMID: 33236266.

407 38. Kontochristopoulos G, Markantoni V, Agiasofitou E, Platsidaki E, Kouris A, Campanati A,
408 et al. Treatment of primary axillary hyperhidrosis with a cream formulation of oxybutynin
409 chloride 10. *Journal of the European Academy of Dermatology and Venereology : JEADV*.
410 2021;35(8):e524-e6. doi: 10.1111/jdv.17297. PubMed PMID: 33893675.

411 39. Chabicovsky M, Winkler S, Soeberdt M, Kilic A, Masur C, Abels C. Pharmacology,
412 toxicology and clinical safety of glycopyrrolate. *Toxicol Appl Pharmacol*. 2019;370:154-69.
413 Epub 2019/03/25. doi: 10.1016/j.taap.2019.03.016. PubMed PMID: 30905688.

414 40. Abels C, Soeberdt M, Kilic A, Reich H, Knie U, Jourdan C, et al. A glycopyrronium
415 bromide 1% cream for topical treatment of primary axillary hyperhidrosis: efficacy and safety
416 results from a phase IIIa randomized controlled trial. *The British journal of dermatology*.
417 2021;185(2):315-22. doi: 10.1111/bjd.19810. PubMed PMID: 33445205.

418 41. Nasir A, Bissonnette R, Maari C, DuBois J, Pene Dumitrescu T, Haddad J, et al. A phase
419 2a randomized controlled study to evaluate the pharmacokinetic, safety, tolerability and clinical

- 420 effect of topically applied Umeclidinium in subjects with primary axillary hyperhidrosis. J Eur
421 Acad Dermatol Venereol. 2018;32(1):145-51. Epub 2017/10/22. doi: 10.1111/jdv.14651.
422 PubMed PMID: 29055158.
- 423 42. Shamseer L, Moher D, Clarke M, Gherzi D, Liberati A, Petticrew M, et al. Preferred
424 reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015:
425 elaboration and explanation. BMJ (Clinical research ed). 2015;350:g7647. doi:
426 10.1136/bmj.g7647. PubMed PMID: 25555855.
- 427 43. Liu HN WH, Yao C, Chen YZ, Liu TT. Advanced methods of data extraction for
428 continuous outcomes in meta-analysis. Chinese Journal of Evidence-based Medicine.
429 2017;17(01):117-21.
- 430 44. Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, et al. Updated guidance
431 for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic
432 Reviews of Interventions. The Cochrane database of systematic reviews. 2019;10:ED000142.
433 doi: 10.1002/14651858.ED000142. PubMed PMID: 31643080.
- 434 45. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE:
435 an emerging consensus on rating quality of evidence and strength of recommendations. BMJ
436 (Clinical research ed). 2008;336(7650):924-6. doi: 10.1136/bmj.39489.470347.AD. PubMed
437 PMID: 18436948.
- 438 46. del Boz J. Systemic treatment of hyperhidrosis. Actas Dermosifiliogr. 2015;106(4):271-7.
439 Epub 2015/02/02. doi: 10.1016/j.ad.2014.11.012. PubMed PMID: 25638324.

440 **Supporting information**

441 S1 Appendix. The PRISMA-P checklist.

442 S2 Appendix. The search strategy for PubMed.

443 S1 Fig. The PRISMA flow diagram of the study selection process.

444

